微創醫療(00853.HK):心脈醫療定增申請獲得上交所審核通過
格隆匯7月13日丨微創醫療(00853.HK)公佈,有關旗下心脈醫療(688016.SH)定增申請事項。於2023年7月13日,上交所已批准建議發行。
根據建議發行,心脈醫療科技可發行最多2159.34萬股股份,以籌集資金髮展項目及用作額外營運資金。建議發行將以符合中國證監會及上交所規定條件的投資者為對象。建議發行的合資格投資者數目將限制於35名以下。概不會根據建議發行向公眾人士發售A股。
據悉,心脈醫療科技主要從事大動脈及外周血管介入業務,為腹部及胸廓大動脈瘤、外周血管疾病、主動脈夾層動脈瘤及其他動靜脈相關疾病的介入治療提供一系列產品及服務。心脈醫療科技的股份於上交所科創板上市。
心脈醫療科技現時由集團擁有46.34%權益及其業績綜合入賬至公司財務報表。預計於建議發行完成後,心脈醫療科技的業績將繼續綜合載入公司業績。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.